Demonstrated reduction in ARR |
Demonstrated reduction in 3-month EDSS progression |
Demonstrated reduction in brain lesions |
||
|
See how MAVENCLAD achieved |
See how MAVENCLAD delivered a 33% |
Discover how MAVENCLAD |
Footnotes and References
Reference
ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; OR=odds ratio
* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.1
- MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
- Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.